PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

@article{Dedes2010PTENDI,
  title={PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors},
  author={K. Dedes and D. Wetterskog and Ana M. Mendes-Pereira and R. Natrajan and M. Lambros and F. Geyer and R. Vatcheva and K. Savage and A. Mackay and C. Lord and A. Ashworth and J. Reis-Filho},
  journal={Science Translational Medicine},
  year={2010},
  volume={2},
  pages={53ra75 - 53ra75}
}
Endometrioid endometrial cancer cell lines harboring PTEN loss of function have impaired homologous recombination response to DNA double-strand breaks and show an exquisite sensitivity to PARP inhibition. Putting PARP Inhibitors on the Map Targeted drug therapies that interfere with specific oncoproteins in certain cancers like lung cancer and chronic myeloid leukemia have shown great promise, but designing targeted therapies for tumors that have lost a tumor suppressor protein has proved… Expand
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
TLDR
PI3K inhibition may be a plausible approach to expand the utility of PARP inhibitors to endometrioid endometrial cancers in a PTEN-deficient setting, as evidenced by reduced clonogenic cell growth and three-dimensional spheroid disintegration. Expand
Development of PARP inhibitors in gynecological malignancies.
TLDR
This is a field rich in opportunity, and the coming years should see a better understanding of which patients should be treating with PARP inhibitors and where these agents should come in over the course of treatment. Expand
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
TLDR
This review will discuss the use of PARP inhibitors in endometrial cancer, summarizing data from preclinical studies and providing an overview of the ongoing trials, with a special focus on the development of combined treatment strategies with PARP inhibitor and immune checkpoint inhibitors. Expand
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors
TLDR
The discovery of a predictive assay for HRD may open the door for clinical trials in non-ovarian gynecologic cancers enriched with patients with HRD, and move cancer treatment towards individualized therapies in order to maximize treatment effect and quality of life. Expand
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
TLDR
The focus of this review will be on pre-clinical data, current clinical trials, and the future of PARP inhibitors in the treatment of ovarian, endometrial, and cervical cancer. Expand
Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo
TLDR
Results of this preclinical trial suggest that orally administered PARP inhibitors in a low estrogenic hormonal milieu can effectively target PTEN-null endometrial tumors, and could personalize the therapy of women afflicted with advanced endometricrial cancer using well-tolerated orally administered therapeutic agents. Expand
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
TLDR
Identifying the population of patients with the greatest potential benefit from PARP inhibitors therapy and the circumstances under which patients are no longer suited for PARP inhibitor therapy are important and better strategies for overcoming resistance to PARP inhibition therapy in ovarian cancers are proposed. Expand
Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease
TLDR
Results suggest that nuclear PTEN subcellular localization in human EndoCA could be diagnostic when considering DDR therapeutic intervention. Expand
PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
TLDR
The clinical development of PARP inhibitors in ovarian cancer is discussed and challenges that need to be addressed are explored if the full potential of these agents is to be realized. Expand
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
TLDR
Targeting both PARP and PI3K might lead to improved personalized therapeutic approaches in endometrial cancer patients with PTEN mutations, which will help to better select patients that are likely to respond to some of the new and costly targeted therapies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
TLDR
The data presented here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours. Expand
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
TLDR
The exquisite sensitivity of these cells to the PARP inhibitor AZD 2281, alone or in combination with cisplatin, provides strong support for AZD2281 as a novel targeted therapeutic against BRCA-deficient cancers. Expand
PTEN/MMAC1 mutations in endometrial cancers.
TLDR
Data indicate that PTEN/MMAC1 is more commonly mutated than any other known gene in endometrial cancers, and may be responsible for several familial neoplastic disorders. Expand
PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Mapping of homozygous deletions on human chromosome 10q23 has led to the isolation of a candidate tumor suppressor gene, PTEN, that appears to be mutated at considerable frequency in human cancers.Expand
Targeted therapy for cancer using PARP inhibitors.
TLDR
The recent identification of mechanisms of cellular resistance to PARP inhibitors may provide indications as to how these drugs may be best used in the clinic. Expand
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
TLDR
It is shown that PARP inhibition has substantial single agent antitumour activity with a wide therapeutic index in homologous DNA repair-defective tumours such as those arising in BRCA1 and BRCa2 mutation carriers. Expand
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
TLDR
The identification of the second mutational event in 10 (43%) tumors establishes PTEN/MMAC1 as a main inactivation target of 10q loss in sporadic prostate cancer. Expand
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
TLDR
BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage. Expand
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
TLDR
Loss of PTEN function by mutational or other mechanisms is an early event in endometrial tumorigenesis that may occur in response to known endocrine risk factors and offers an informative immunohistochemical biomarker for premalignant disease. Expand
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma
TLDR
It is found that PTEN promoter methylation is relatively frequent in endometrial carcinoma and its association with metastatic disease and microsatellite instability implicates its importance in the development of this tumor type. Expand
...
1
2
3
4
5
...